ST Germain D J Co. Inc. raised its holdings in ResMed Inc. (NYSE:RMD) by 18.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,347 shares of the medical equipment provider’s stock after buying an additional 1,625 shares during the period. ST Germain D J Co. Inc.’s holdings in ResMed were worth $1,774,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also added to or reduced their stakes in the company. Newfound Research LLC bought a new position in shares of ResMed in the third quarter valued at $29,000. James Investment Research Inc. bought a new position in shares of ResMed in the third quarter valued at $37,000. Freestone Capital Holdings LLC bought a new position in shares of ResMed in the third quarter valued at $45,000. CX Institutional lifted its stake in shares of ResMed by 37.7% in the second quarter. CX Institutional now owns 241 shares of the medical equipment provider’s stock valued at $46,000 after buying an additional 66 shares in the last quarter. Finally, Ellevest Inc. lifted its stake in shares of ResMed by 31.6% in the third quarter. Ellevest Inc. now owns 283 shares of the medical equipment provider’s stock valued at $49,000 after buying an additional 68 shares in the last quarter. 69.38% of the stock is currently owned by hedge funds and other institutional investors.
RMD has been the topic of a number of recent analyst reports. Bank of America raised shares of ResMed from an “underperform” rating to a “neutral” rating and set a $186.00 price target on the stock in a research report on Tuesday, October 27th. Morgan Stanley lowered shares of ResMed from an “overweight” rating to an “equal weight” rating in a research report on Thursday, August 6th. UBS Group raised shares of ResMed from a “neutral” rating to a “buy” rating and set a $210.00 price target on the stock in a research report on Monday, November 2nd. JPMorgan Chase & Co. raised shares of ResMed from an “underweight” rating to a “neutral” rating and set a $165.00 price target on the stock in a research report on Friday, October 30th. Finally, Credit Suisse Group raised shares of ResMed from a “neutral” rating to an “outperform” rating in a research report on Friday, October 30th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company’s stock. ResMed has an average rating of “Hold” and an average price target of $188.50.
ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, October 29th. The medical equipment provider reported $1.27 EPS for the quarter, topping the consensus estimate of $0.98 by $0.29. The business had revenue of $751.90 million for the quarter, compared to analyst estimates of $709.47 million. ResMed had a net margin of 21.02% and a return on equity of 30.34%. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.93 earnings per share. Equities analysts anticipate that ResMed Inc. will post 4.75 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 17th. Shareholders of record on Thursday, November 12th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.74%. The ex-dividend date of this dividend is Tuesday, November 10th. ResMed’s dividend payout ratio is 32.77%.
In other news, COO Robert Andrew Douglas sold 1,125 shares of ResMed stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $176.72, for a total value of $198,810.00. Following the completion of the transaction, the chief operating officer now owns 24,620 shares in the company, valued at $4,350,846.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Justin Leong sold 7,740 shares of ResMed stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $211.36, for a total transaction of $1,635,926.40. Following the completion of the transaction, the insider now owns 33,126 shares of the company’s stock, valued at approximately $7,001,511.36. The disclosure for this sale can be found here. Insiders sold 31,350 shares of company stock valued at $5,797,434 in the last quarter. Corporate insiders own 1.33% of the company’s stock.
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service.
Featured Story: Pattern Day Trader – What is the PDT Rule?
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.